Fluphenazine Hydrochloride

CHEMBL1448187 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

510.4 g/mol

LogP

—

Phase

4

This hydrochloride salt of fluphenazine is an oral antipsychotic used in the treatment of schizophrenia and psychotic disorders by blocking dopamine receptors in the brain. It requires careful dose adjustment to balance therapeutic effects with movement-related side effects.

Moleküler Ağırlık

510,4000 g/mol

TPSA

55,30 Å²

Terapötik Alanlar

Schizophrenia Generalized Anxiety Disorder Psoriasis

Etki Mekanizması

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

Cl.Cl.OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C22H26F3N3OS.2ClH/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;;/h1-2,4-7,16,29H,3,8-15H2;2*1H

Molecular Formula

C22H28Cl2F3N3OS

HBD / HBA

3 / 8

Döndürülebilir Bağlar

6

Ağır Atomlar

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This hydrochloride salt of fluphenazine is an oral antipsychotic used in the treatment of schizophrenia and psychotic disorders by blocking dopamine receptors in the brain. It requires careful dose adjustment to balance therapeutic effects with movement-related side effects.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1448187. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 67356. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Fluphenazine Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C22H28Cl2F3N3OS
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.